Clinical trials after COVID-19
https://exploristics.com/wp-content/uploads/2020/08/Clinical-trials-after-COVID-19-558-344.jpg
558
344
Exploristics
https://exploristics.com/wp-content/uploads/2020/08/Clinical-trials-after-COVID-19-558-344.jpg
Aiden Flynn, CEO 11 August 2020
The challenges faced by the Pharmaceutical Industry have been well documented: the high costs of clinical trials; the high rates of attrition; higher regulatory scrutiny; limited scope to pay high costs of new medicines; …